America's largest brewers are responding to a notable shift in consumer behavior, with miniature beer cans and bottles—often called 'ponies'—emerging as a fast-growing trend. This pivot is driven in part by the increasing use of GLP-1 weight-loss medications, such as Ozempic, Wegovy, and Zepbound, which are leading millions of Americans to moderate their alcohol consumption.
The crucial Fourth of July holiday weekend, traditionally a peak time for beer sales, highlights this industry adaptation. According to the Beer Institute, beer sales typically surge by about 37 percent above average during the week of Independence Day.
Major beverage companies, including Sierra Nevada and Constellation Brands, the owner of Corona and Modelo, are expanding their offerings of seven- to nine-ounce beers in response to growing consumer demand. "We're bullish on what ponies can add," Craig Purser, chief executive of the National Beer Wholesalers Association, told The Wall Street Journal. "Consumers don't have to make a 12-ounce decision."
This trend aligns with broader changes in American drinking habits. While health-conscious consumers have been drinking less alcohol for several years, the rapid adoption of GLP-1 medications appears to be accelerating this moderation.
Research published by OC&C Strategy Consultants indicates that GLP-1 medications are expected to cause a lasting change in food and beverage purchasing habits through at least 2031. The firm estimates current usage at about 12 percent of Americans, with potential to rise to 15 percent to 18 percent within five years.
These medications are significantly impacting alcohol spending, with a report finding that alcohol expenditure decreases by approximately 7 percent after a user has been on GLP-1 medication for a year. This makes alcohol one of the categories most affected by the drugs. Drinkaware research also suggests that many users of these medications are consciously moderating their intake by choosing smaller quantities or drinking less frequently. These altered habits are beginning to influence social circles, contributing to a wider cultural shift toward moderation.
Brewers believe that smaller servings can help retain consumers who still desire an occasional beer without the commitment of a full-sized container. Nick Fink, chief executive of Constellation Brands, stated that the company sees substantial potential in the "pony" trend. "We're leaning in to it. I think you'll see extensions into it," Fink said, noting that GLP-1 drug usage offers an opportunity to "expand the utility of small beers and move into little treat culture."
Constellation Brands has offered miniature Coronita bottles for years and is now extending the format to Pacifico due to strong customer interest. Sierra Nevada also reported significant success after introducing miniature cans of its Pils beer last year, leading to plans for expanded distribution and larger multipacks. Ellie Preslar, Sierra Nevada's chief growth officer, commented that the appeal of the smaller size was broader than anticipated, resonating with individuals seeking to moderate their intake, such as parents who want a treat without overconsumption.
The concept of smaller beer servings is not entirely new, with pony bottles dating back to the late 19th century and Coors introducing an aluminum pony can in the 1950s. Rolling Rock's miniature bottles gained popularity in the 1980s. The current resurgence, however, is driven by different factors related to changing consumer health and lifestyle choices.
Industry distributors report that smaller beers are outperforming many traditional sizes, particularly in warmer regions. While miniature beers still represent a small fraction of total beer sales, brewers increasingly view them as a strategic fit for a future where consumers prioritize occasional indulgence in smaller portions, adapting to evolving drinking habits. [IMAGE2: The tiny beers, often known as 'ponies,' are emerging as one of the industry's fastest-growing trends just as the crucial Fourth of July holiday gets underway] [IMAGE4: As millions of Americans embrace GLP-1 weight-loss medications beer companies are racing to stock supermarket shelves with miniature cans and bottles that offer a smaller serving] [IMAGE3: Research published this week by OC&C Strategy Consultants found GLP-1 medications are expected to create a persistent shift in food and drink purchasing habits through at least 2031]